Current Infectious Disease Reports

, Volume 12, Issue 3, pp 198–203 | Cite as

Pulmonary Nontuberculous Mycobacterial Disease: New Insights into Risk Factors for Susceptibility, Epidemiology, and Approaches to Management in Immunocompetent and Immunocompromised Patients



Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and cause a wide range of diseases in humans. Pulmonary involvement, the most common disease manifestation of NTM infection, is being increasingly encountered in clinical settings. In addition, specific phenotypic and genetic characteristics of persons predisposed to contract pulmonary NTM disease are now beginning to be recognized. Prior to treatment, patients should meet clinical and microbiologic criteria for NTM disease. Treatment involves prolonged courses of antibiotics in various combination regimens that are often discontinued because of serious side effects. In some cases, complete cure of pulmonary disease is difficult to achieve. Rather, clinical improvement may be a more feasible goal. Surgical treatment is warranted for select patients.


Nontuberculous mycobacteria Bronchiectasis Mycobacterium avium complex Mycobacterium abscessus Mycobacterium kansasii Cystic fibrosis 



This work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

The views expressed in this article are those of the authors and do not necessarily reflect those of the US Department of Health and Human Services.


Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance

  1. 1.
    •• Griffith DC, Aksamit T, Brown-Elliott BA, et al.: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367–416. This article provides the most up-to-date official guidelines for the diagnosis and management of pulmonary infections caused by nontuberculous mycobacteria endorsed by the American Thoracic Society and the Infectious Diseases Society of America.Google Scholar
  2. 2.
    Marras TK, Chedore P, Ying AM, et al.: Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. Thorax 2007, 62:661–666.CrossRefPubMedGoogle Scholar
  3. 3.
    Khan K, Wang J, Marras TK: Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007, 176:306–313.CrossRefPubMedGoogle Scholar
  4. 4.
    Billinger ME, Olivier KN, Viboud C, et al.: Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998–2005. Emerging Infect Dis 2009, 15:1562–1569.PubMedGoogle Scholar
  5. 5.
    Edwards LB, Acquaviva FA, Livesay VT, et al.: An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969, 99(Suppl):1–132.Google Scholar
  6. 6.
    Kirschner R, Parker B, Falkinham J: Epidemiology of infection by nontuberculous mycobacteria: Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium scrofulaceum in acid, brown-water swamps of the Southeastern United States and their association with environmental variables. Am Rev Respir Dis 1992, 145:271–275.PubMedGoogle Scholar
  7. 7.
    Aksamit TR: Mycobacterium avium complex pulmonary disease in patients with pre-existing lung disease. Clin Chest Med 2002, 23:643–653.CrossRefPubMedGoogle Scholar
  8. 8.
    Noone PG, Leigh MW, Sannuti A, et al.: Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004, 169:459–467.CrossRefPubMedGoogle Scholar
  9. 9.
    Olivier KN, Weber DJ, Wallace RJ, et al.: Nontuberculous mycobacteria: 1. Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828–834.CrossRefPubMedGoogle Scholar
  10. 10.
    Ebert DL, Olivier KN: Nontuberculous mycobacteria in the setting of cystic fibrosis. Clin Chest Med 2002, 23:655–663.CrossRefPubMedGoogle Scholar
  11. 11.
    Melia E, Freeman AF, Shea YR, et al.: Pulmonary nontuberculous mycobacterial infections in hyper-IgE syndrome. J Allergy Clin Immunol 2009, 124:617–618.CrossRefPubMedGoogle Scholar
  12. 12.
    Reich JM, Johnson RE: Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern: the Lady Windermere syndrome. Chest 1992, 101:1605–1609.CrossRefPubMedGoogle Scholar
  13. 13.
    Dhillon SS, Watanakunakorn C: Lady Windermere syndrome: middle lobe bronchiectasis and Mycobacterium avium complex infection due to voluntary cough suppression. Clin Infect Dis 2000, 30:572–575.CrossRefPubMedGoogle Scholar
  14. 14.
    • Kim RD, Greenberg DE, Ehrmantraut ME, et al.: Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008, 178:1066–1074. This article provides an excellent study of the phenotypic characteristics of women without underlying pulmonary disease who develop pulmonary nontuberculous mycobacterial disease.Google Scholar
  15. 15.
    Colombo RE, Hill SC, Claypool RJ, et al.: Familial clustering of pulmonary nontuberculous mycobacterial disease. Chest 2009, Epub ahead of print..Google Scholar
  16. 16.
    Freeman AF, Olivier KN, Rubio TT, et al.: Intrathoracic nontuberculous mycobacterial infections in otherwise healthy children. Pediatr Pulmonol 2009, 44:1051–1056.CrossRefPubMedGoogle Scholar
  17. 17.
    •• Colombo RE, Olivier KN: Diagnosis and treatment of infections caused by rapidly growing mycobacteria. Semin Respir Crit Care Med 2008, 29:577–588. This article provides a review of the spectrum of disease and management of infection due to rapidly growing mycobacteria, especially Mycobacterium abscessus.Google Scholar
  18. 18.
    Bange FC, Bottger EC: Improved decontamination method for recovering mycobacteria from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2002, 21:546–548.CrossRefPubMedGoogle Scholar
  19. 19.
    Nishimura T, Hasegawa N, Fujita Y, et al.: Serodiagnostic contributions of antibody titers against mycobacterial lipid antigens in Mycobacterium avium complex pulmonary disease. Clin Infect Dis 2009, 49:529–535.CrossRefPubMedGoogle Scholar
  20. 20.
    Ballarino GB, Olivier KN, Claypool RJ, et al.: Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009, 103:1448–1455.CrossRefPubMedGoogle Scholar
  21. 21.
    Wallace RJ, Zhang Y, Brown BA, et al.: Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis. Am J Respir Crit Care Med 1998, 158:1235–1244.PubMedGoogle Scholar
  22. 22.
    Research Committee of the British Thoracic Society: Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardized treatment. Int J Tuberc Lung Dis 2002, 6:628–634.Google Scholar
  23. 23.
    Wallace RJ Jr, Brown BA, Griffith DE, et al.: Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994, 149:1335–1341.PubMedGoogle Scholar
  24. 24.
    Griffith DE, Brown BA, Girard WM, et al.: Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. Clin Infect Dis 1996, 23:983–989.PubMedGoogle Scholar
  25. 25.
    Griffith DE, Brown-Elliott BA, Longsjoen B, et al.: Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 174:928–934.CrossRefPubMedGoogle Scholar
  26. 26.
    Lam PK, Griffith DE, Aksamit TR, et al.: Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006, 173:128–1289.CrossRefGoogle Scholar
  27. 27.
    Pezzia W, Raleigh JW, Bailey MC, et al.: Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981, 3:1035–1039.PubMedGoogle Scholar
  28. 28.
    Banks J, Hunter AM, Campbell IA, et al.: Pulmonary infection with Mycobacterium kansasii in Wales, 1970–79: review of treatment and response. Thorax 1983, 38:271–274.CrossRefPubMedGoogle Scholar
  29. 29.
    Nash KA, Brown-Elliott BA, Wallace RJ: A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009, 53:1367–1376.CrossRefPubMedGoogle Scholar
  30. 30.
    Jeon K, Jung Kwon O, Lee NY, et al.: Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009, 180:896–902.Google Scholar
  31. 31.
    Brown-Elliott BA, Crist CJ, Mann LB, et al.: In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob Agents Chemother 2003, 47:1736–1738.CrossRefPubMedGoogle Scholar
  32. 32.
    Cavusoglu C, Soyler I, Akinci P: Activities of linezolid against nontuberculous mycobacteria. New Microbiol 2007, 30:411–414.PubMedGoogle Scholar
  33. 33.
    Chalermskulrat W, Sood N, Neuringer IP, et al.: Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006, 61:507–513.CrossRefPubMedGoogle Scholar
  34. 34.
    Zaidi S, Elidemir O, Heinle JS, et al.: Mycobacterium abscessus in cystic fibrosis lung transplant recipients: report of 2 cases and risk for recurrence. Transpl Infect Dis 2009, 11:243–248.CrossRefPubMedGoogle Scholar

Copyright information

© US Government 2010

Authors and Affiliations

  1. 1.Immunopathogenesis SectionLaboratory of Clinical Infectious Diseases/NIAIDBethesdaUSA

Personalised recommendations